Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2008 Feb 29;283(9):5452-9.
doi: 10.1074/jbc.M707834200. Epub 2007 Oct 25.

Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase

Affiliations

Pre-steady-state kinetic studies establish entecavir 5'-triphosphate as a substrate for HIV-1 reverse transcriptase

Robert A Domaoal et al. J Biol Chem. .

Abstract

The novel 2'-deoxyguanosine analog Entecavir (ETV) is a potent inhibitor of hepatitis B virus (HBV) replication and is recommended for treatment in human immunodeficiency virus type 1 (HIV-1) and HBV-co-infected patients because it had been reported that ETV is HBV-specific. Recent clinical observations, however, have suggested that ETV may indeed demonstrate anti-HIV-1 activity. To investigate this question at a molecular level, kinetic studies were used to examine the interaction of 5'-triphosphate form of ETV with wild type (WT) HIV-1 reverse transcriptase (RT) and the nucleoside reverse transcriptase inhibitor-resistant mutation M184V. Using single turnover kinetic assays, we found that HIV-1 WT RT and M184V RT could use the activated ETV triphosphate metabolite as a substrate for incorporation. The mutant displayed a slower incorporation rate, a lower binding affinity, and a lower incorporation efficiency with the 5'-triphosphate form of ETV compared with WT RT, suggesting a kinetic basis for resistance. Our results are supported by cell-based assays in primary human lymphocytes that show inhibition of WT HIV-1 replication by ETV and decreased susceptibility of the HIV-1 containing the M184V mutation. This study has important therapeutic implications as it establishes ETV as an inhibitor for HIV-1 RT and illustrates the mechanism of resistance by the M184V mutant.

PubMed Disclaimer

Figures

FIGURE 1.
FIGURE 1.. Incorporation of ETVTP by HIV-1 RT.
A, the structure of ETVTP. B, the 24-nucleotide (nt) DNA primer annealed to a 36-nt DNA template that was used for all experiments. The arrow denotes the position of the next dNTP to be incorporated. C, products from single-turnover incorporation of ETVTP alone (100 μm) or with the natural dNTPs (100 μm of each) into the D24/D36 primer/template (50 nm) by WT RT (250 nm). Lanes represent the increasing reaction time; Lane 1, 0 min; lane 2, 1 min; lane 3, 2 min; lane 4, 3 min; lane 5, 5 min; lane 6, 10 min. The sizes of the DNA primer (24-mer) and the extended products are indicated. D, products from single-turnover incorporation of dGTP alone (100 μm), all four natural dNTPs (100 μm each) and CBVTP alone (200 μm) into the D24/D36 primer/template (50 nm) by WT RT (250 nm). Lanes represent the increasing reaction times as described above. The sizes of the DNA primer (24-mer) and the extended products are indicated.
FIGURE 2.
FIGURE 2.. Concentration dependence of the observed rate on ETVTP concentration for WT HIV-1 RT.
A, single-turnover incorporation was measured by mixing a preincubated solution of RT (250 nm) and DNA/DNA primer/template (50 nm) with various concentrations of ETVTP (curves displayed represent 0.5 μm (○), 1 μm (□), 5 μm (◇), 20 μm (●) and 50 μm (△)) and MgCl2 (10 mm) at 37 °C (all concentrations are final after mixing). B, Kd,ETVTP curve was generated from all ETVTP concentrations tested (500 nm to 50 μm) where the observed rate (kobsd) was plotted against ETVTP concentration. The fit to the data gives an equilibrium binding constant (Kd,ETVTP) of 2.23 ± 0.67 μm and a maximum rate of incorporation (kpol) of 0.107 ± 0.007 s−1. C, pre-steady-state burst kinetics of incorporation of ETVMP into a DNA/DNA primer/template by WT RT were measured by mixing a preincubated solution of RT (100 nm) and primer/template (300 nm) with ETVTP (50 μm) and Mg2+ (10 mm) under rapid quench conditions (all concentrations are final after mixing). The reaction was quenched at indicated times and analyzed by 20% sequencing gel electrophoresis. The solid line represents a fit to a burst equation with an amplitude (A) equal to 79 ± 12 nm, an observed first-order rate constant for the burst phase (kobsd) equal to 0.125 ± 0.031 s−1, and an observed rate for the linear phase (kss) equal to 0.020 ± 0.006 s−1.
FIGURE 3.
FIGURE 3.. Effect of ETVTP versus dGTP incorporation on primer/template binding to WT HIV-1 RT.
Burst amplitudes were measured at varying concentrations of D24/D36 using dGTP (■) or ETVTP (●) as the substrate for incorporation. Data were fit to the quadratic equation (see “Experimental Procedures”). The Kd,DNA for D24/D36 during dGTP incorporation was 31.3 ± 9.3 nm, whereas during ETVTP incorporation the Kd,DNA was 127.5 ± 4.9 nm.
FIGURE 4.
FIGURE 4.. Overlap between ETV and the next 2′-deoxyribose in the primer chain.
The surface of the methylene moiety is colored orange, and the closest atoms in the next 2′-deoxyribose are in gray. The green arrow near the lower left corner shows the largest overlap found when ETV is in position +5 in the primer.

References

    1. Ganem D, Pollack JR, and Tavis J (1994) Infect. Agents Dis 3, 85–93 - PubMed
    1. Locarnini SA, Civitico GM, and Newbold JE (1996) Antiviral Chem. Chemother 7, 53–64
    1. Seeger C, Summers J, and Mason WS (1991) Curr. Top. Microbiol. Immunol 168, 41–60 - PubMed
    1. Seifer M, Hamatake RK, Colonno RJ, and Standring DN (1998) Antimicrob. Agents Chemother 42, 3200–3208 - PMC - PubMed
    1. Innaimo SF, Seifer M, Bisacchi GS, Standring DN, Zahler R, and Colonno RJ (1997) Antimicrob. Agents Chemother 41, 1444–1448 - PMC - PubMed

Publication types

MeSH terms